Pharmacyclics, Inc.

The University of Texas System

Lumiphore, Inc.

Other

Board of Trustees, Univ. of Tx Sys.

Darren Magda

Jonathan L Sessler

Tarak D Mody

Jide Xu

Gregory W Hemmi

Brent L Iverson

Nathaniel G Butlin

Meredith Wright

Richard A Miller

Vladimir A Kr Al

Shaun P Crofts

David Tatum

Petra I Sansom

Vladimir A Kral

Anthony M Harriman

William C Dow

Nikolay Gerasimchuk

Greg Hemmi

Dale Miles

Cheryl Lepp

Daniel A Smith

Joseph J Buggy

Norbert Purro

Stuart W Young

Richard E Thomas

Joan F Carvalho

Pavel Anzenbacher, Jr

Shanthi Adimoolam

Petra L Jansen

Kevin L Ross

Sharon Hannah

Nathaniel Butlin

Richard Miller

The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.

Macrocyclic ligands with pendant chelating moieties and complexes thereof

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

Macrocycles

Di-macrocycles

Functionalized linear ligands and complexes thereof

Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.

Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy

Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.

Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer

The radiation sensitization potential of a candidate compound can be screened by determine its ability to generate one or more reactive oxygen species under appropriate conditions. Compounds determined to have radiation sensitization potential are employed in methods for treating atheroma, tumors and other neoplastic tissue as well as other conditions that typically responsive to radiation sensitization.

Methods and compositions for treating atheroma, tumors and other neoplastic tissues

Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein.

Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Texaphyrin coordination compounds and uses thereof

Growing community of inventors

Cupertino, CA, United States of America

Darren Magda